Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other analysts also recently weighed in on the stock. Zacks Research raised shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $247.50.

Enlivex Therapeutics Price Performance

Shares of ENLV opened at $1.58 on Friday. The business has a fifty day moving average of $6.08 and a 200 day moving average of $11.47. The company has a market cap of $26.59 million, a PE ratio of -0.19 and a beta of 1.60. Enlivex Therapeutics has a 52-week low of $1.53 and a 52-week high of $31.50.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ENLV. XTX Topco Ltd increased its holdings in Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after acquiring an additional 19,132 shares in the last quarter. Bank of America Corp DE lifted its holdings in Enlivex Therapeutics by 53.2% during the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after purchasing an additional 45,303 shares in the last quarter. Virtu Financial LLC purchased a new position in Enlivex Therapeutics during the fourth quarter valued at $33,000. Jane Street Group LLC lifted its holdings in Enlivex Therapeutics by 244.1% during the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after purchasing an additional 52,553 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of Enlivex Therapeutics in the third quarter valued at about $57,000. 1.02% of the stock is owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.